Medexus Pharmaceuticals Inc. (TSX:MDP)
Canada
· Delayed Price · Currency is CAD 3.100
-0.060 (-1.90%)
At close: Mar 6, 2026
Medexus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 99.43 | 108.33 | 113.05 | 108.1 | 76.7 | 79.66 | Upgrade
|
| Revenue Growth (YoY) | -9.23% | -4.18% | 4.59% | 40.93% | -3.72% | 43.52% | Upgrade
|
| Cost of Revenue | 36.44 | 44.82 | 47.99 | 42.33 | 33.03 | 32.18 | Upgrade
|
| Gross Profit | 63 | 63.51 | 65.07 | 65.77 | 43.67 | 47.48 | Upgrade
|
| Selling, General & Admin | 47.47 | 43.18 | 44.87 | 48.25 | 44.03 | 36.17 | Upgrade
|
| Research & Development | 1.92 | 1.23 | 1.61 | 2.94 | 5.87 | 4.6 | Upgrade
|
| Amortization of Goodwill & Intangibles | 9.43 | 6.93 | 5.56 | 5.73 | 5.75 | 5.47 | Upgrade
|
| Operating Expenses | 59.11 | 51.59 | 52.28 | 57.28 | 56.05 | 46.75 | Upgrade
|
| Operating Income | 3.89 | 11.92 | 12.79 | 8.49 | -12.38 | 0.73 | Upgrade
|
| Interest Expense | -6.18 | -8.2 | -13.36 | -13.61 | -12.22 | -9.82 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -1.69 | -0.15 | 1.99 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.42 | 1.41 | 2.68 | 2.64 | 23.55 | -22.3 | Upgrade
|
| EBT Excluding Unusual Items | 1.13 | 5.14 | 2.1 | -4.17 | -1.2 | -29.39 | Upgrade
|
| Merger & Restructuring Charges | -0.82 | -0.9 | -1.11 | -0.88 | -0.87 | -2.11 | Upgrade
|
| Asset Writedown | -0.34 | -2.8 | -0.89 | - | -1.75 | - | Upgrade
|
| Pretax Income | -0.03 | 1.44 | 0.11 | -5.04 | -3.82 | -31.5 | Upgrade
|
| Income Tax Expense | 0.25 | -0.81 | 0.32 | -6.26 | -0.94 | -3.24 | Upgrade
|
| Net Income | -0.27 | 2.25 | -0.21 | 1.22 | -2.88 | -28.26 | Upgrade
|
| Net Income to Common | -0.27 | 2.25 | -0.21 | 1.22 | -2.88 | -28.26 | Upgrade
|
| Shares Outstanding (Basic) | 32 | 26 | 22 | 20 | 19 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 27 | 22 | 21 | 20 | 15 | Upgrade
|
| Shares Change (YoY) | 28.99% | 18.76% | 8.76% | 3.36% | 30.65% | 5.83% | Upgrade
|
| EPS (Basic) | -0.01 | 0.09 | -0.01 | 0.06 | -0.15 | -1.86 | Upgrade
|
| EPS (Diluted) | -0.01 | 0.08 | -0.01 | 0.06 | -0.15 | -1.86 | Upgrade
|
| Free Cash Flow | 17.16 | 23.85 | 18.66 | -1.51 | -1.28 | 4.92 | Upgrade
|
| Free Cash Flow Per Share | 0.54 | 0.90 | 0.84 | -0.07 | -0.06 | 0.32 | Upgrade
|
| Gross Margin | 63.35% | 58.62% | 57.56% | 60.84% | 56.94% | 59.60% | Upgrade
|
| Operating Margin | 3.91% | 11.00% | 11.31% | 7.85% | -16.13% | 0.92% | Upgrade
|
| Profit Margin | -0.27% | 2.07% | -0.19% | 1.13% | -3.75% | -35.48% | Upgrade
|
| Free Cash Flow Margin | 17.26% | 22.02% | 16.51% | -1.39% | -1.67% | 6.18% | Upgrade
|
| EBITDA | 13.44 | 18.94 | 18.44 | 14.37 | -6.46 | 6.35 | Upgrade
|
| EBITDA Margin | 13.52% | 17.48% | 16.31% | 13.30% | -8.42% | 7.98% | Upgrade
|
| D&A For EBITDA | 9.55 | 7.02 | 5.66 | 5.88 | 5.92 | 5.62 | Upgrade
|
| EBIT | 3.89 | 11.92 | 12.79 | 8.49 | -12.38 | 0.73 | Upgrade
|
| EBIT Margin | 3.91% | 11.00% | 11.31% | 7.85% | -16.13% | 0.92% | Upgrade
|
| Effective Tax Rate | - | - | 301.89% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.